ABIVAX Société Anonyme Dirección

Dirección controles de criterios 1/4

El CEO de ABIVAX Société Anonyme es Marc M. de Garidel, nombrado en May 2023, tiene una permanencia de menos de un año. posee directamente un 0.061% de las acciones de la empresa, con un valor de €366.57K. La antigüedad media del equipo directivo y de la junta directiva es de 0.5 años y 4.8 años, respectivamente.

Información clave

Marc M. de Garidel

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	0.06%
Permanencia media de la dirección	less than a year
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Marc M. de Garidel (65 yo)

less than a year

Permanencia

Mr. Marc M. P. de Garidel, M.B.A., serves as CEO & Interim Chair of Board at ABIVAX Société Anonyme since May 5, 2023. He has been the Chief Executive Officer of CinCor Pharma, Inc. since July 2021 and has...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Philippe Pouletty	Founder & Director	no data	sin datos	0.44% € 2.6m
Marc M. de Garidel	CEO & Interim Chair of Board	less than a year	sin datos	0.061% € 366.6k
Didier Blondel	EVP, CFO & Board Secretary	6.9yrs	sin datos	0.00060% € 3.6k
Didier Scherrer	Chief Scientific Officer	less than a year	sin datos	0.057% € 343.8k
Patrick Malloy	Senior Vice President of Investor Relations	less than a year	sin datos	sin datos
Ida Hatoum	Chief People Officer	less than a year	sin datos	sin datos
Pierre Courteille	Chief Business Officer	no data	sin datos	0% € 0
Jérôme Denis	Executive Vice President of Process Development & Manufacturing	less than a year	sin datos	sin datos
Sheldon Sloan	Chief Medical Officer	less than a year	sin datos	sin datos
Michael Ferguson	Chief Commercial Officer	less than a year	sin datos	sin datos

0.5yrs

Permanencia media

60yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de ABVXp no se considera experimentado ( 0.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Philippe Pouletty	Founder & Director	9yrs	sin datos	0.44% € 2.6m
Marc M. de Garidel	CEO & Interim Chair of Board	less than a year	sin datos	0.061% € 366.6k
Christian Brechot	Member of Scientific Advisory Board	6.2yrs	sin datos	sin datos
Christian Trepo	Member of Scientific Advisory Board	no data	sin datos	sin datos
Lawrence Stanberry	Member of Scientific Advisory Board	no data	sin datos	sin datos
Troy Ignelzi	Independent Director	less than a year	sin datos	sin datos
Christoph Huber	Member of Scientific Advisory Board	no data	sin datos	sin datos
Claude Bertrand	Member of Scientific Advisory Board	4.2yrs	€4.94k	sin datos
Luc Teyton	Member of Scientific Advisory Board	no data	sin datos	sin datos
June Lee	Independent Director	less than a year	sin datos	sin datos
Corinna Bonsen-Thomas	Independent Non-Executive Director	6.5yrs	€22.89k	0% € 0
Ian McGowan	Chairman of Scientific Advisory Board	5.5yrs	sin datos	sin datos

4.8yrs

Permanencia media

64.5yo

Promedio de edad

Junta con experiencia: La junta directiva de ABVXp se considera experimentada (4.8 años de antigüedad promedio).

ABIVAX Société Anonyme Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Abivax SA Announces Board Observer & Advisor Appointments

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Insufficient new directors

Insufficient new directors

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Insufficient new directors

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Insufficient new directors

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

New 90-day high: €28.90

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad